<DOC>
	<DOCNO>NCT01829321</DOCNO>
	<brief_summary>- Approximately 45 patient suffer mild moderate ulcerative colitis examine side effect ( safety tolerability ) may occur take GLPG0974 match placebo ( 2:1 ratio ) 28 day . - During course study , patient also evaluate improvement disease activity different efficacy measure , amount GLPG0974 present blood determine ( PK ) effect GLPG0974 select biomarkers ( PD ) blood , colon biopsy faeces explore .</brief_summary>
	<brief_title>Safety , Efficacy , Pharmacokinetic Pharmacodynamic Study GLPG0974 Subjects With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Key Men woman 18 75 year age inclusive , day signing inform consent document history UC . Presence mildtomoderately active ulcerative colitis evidence clinical sign endoscopy . Medication : 5ASA . Absence infectious colitis . Key History sensitivity component study drug Any concurrent illness , condition , disability clinically significant abnormality ( include lab test ) represent safety risk , may affect interpretation data , may prevent subject safely complete assessment Positive serology HIV 1 2 hepatitis B C , history HIV hepatitis . History active infection require intravenous antibiotic within past four week prior randomization . History bowel surgery , presence history intestinal malignancy . Suspicion Crohn 's disease , indeterminate colitis , microscopic colitis , ischaemic colitis radiationinduced colitis . History low GI bleed disorder , UC . A history significant psychological , neurologic , hepatic , renal , endocrine , cardiovascular , gastrointestinal ( UC ) , pulmonary metabolic disease . History tuberculosis ( TB ) infection . Treatment systemic corticosteroid within 1 week prior randomization . Treatment TNFÎ± inhibitor biologics within 2 month prior randomization . Treatment immunosuppressant , initiate change within 3 month prior randomization . Current use probiotic prebiotic preparation Regular daily use NSAIDs , within 7 day prior randomization . Administration experimental therapy within 90 day 5x halflife . History drug alcohol abuse . Pregnant lactating woman . Medical , psychiatric , cognitive , condition compromise subject 's ability complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>